News

Net profit of Gufic BioSciences rose 183.68% to Rs 21.90 crore in the quarter ended March 2026 as against Rs 7.72 crore during the previous quarter ended March 2025. Sales rose 22.83% to Rs 251.82 crore in the quarter ended March 2026 as against Rs 205.02 crore during the previous quarter ended March 2025.For the full year,net profit declined 7.81% to Rs 64.21 crore in the year ended March 2026 as against Rs 69.65 crore during the previous year ended March 2025. Sales rose 15.15% to Rs 944.01 crore in the year ended March 2026 as against Rs 819.81 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales251.82205.02 23 944.01819.81 15 OPM %18.7512.87 -16.0316.60 - PBDT36.6018.37 99 117.38115.21 2 PBT28.9510.52 175 86.5594.14 -8 NP21.907.72 184 64.2169.65 -8 Powered by Capital Market - Live News

Gufic BioSciences announced that the Board of Directors of the Company at its meeting held on 29 May 2026, inter alia, have recommended the final dividend of Rs 0.1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.

Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 29 May 2026.

Net profit of Gufic BioSciences declined 35.68% to Rs 12.42 crore in the quarter ended December 2025 as against Rs 19.31 crore during the previous quarter ended December 2024. Sales rose 11.37% to Rs 231.41 crore in the quarter ended December 2025 as against Rs 207.79 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales231.41207.79 11 OPM %14.2516.33 - PBDT25.4130.88 -18 PBT17.7226.26 -33 NP12.4219.31 -36 Powered by Capital Market - Live News

Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 13 February 2026.Powered by Capital Market - Live News